World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
43332
World Ranking
7591
National Ranking
743

Overview

Brian Gazzard is affiliated with St Bartholomew's Hospital in the United Kingdom. Their research primarily addresses HIV/AIDS with a focus on treatment, prevention, and public health strategies.

The scientist's fields of study include Medicine and Immunology and Microbiology, with subfields covering Infectious Diseases, Virology, Epidemiology, and Sociology and Political Science.

Brian Gazzard's main research topics encompass HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, HIV Research and Treatment, as well as issues related to HIV, Drug Use, Sexual Risk, and Sex work and related issues.

Their recent publications are as follows:

  • HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment (2023, The Lancet HIV)
  • 2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings (2021, Journal of Antimicrobial Chemotherapy)
  • Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT) (2024, EClinicalMedicine)

Frequent collaborators in their research include Carlo Torti, Alejandro Arenas-Pinto, Amanda Clarke, Ian Williams, and Margaret Johnson.

Brian Gazzard's work is published in several scientific venues including The Lancet HIV, EClinicalMedicine, and the Journal of Antimicrobial Chemotherapy.

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

    Sheena McCormack;David T. Dunn;Monica Desai;David I. Dolling

  • Antiretroviral Therapy in Adults: Updated Recommendations of the International AIDS Society–USA Panel

    Charles C. J. Carpenter;David A. Cooper;Margaret A. Fischl;Jose M. Gatell

  • Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

    Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  • Treatment for adult HIV infection : 2006 recommendations of the international AIDS society-USA panel

    Scott M. Hammer;Michael S. Saag;Mauro Schechter;Julio S. G. Montaner

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

    Graeme J. Moyle;Brian G. Gazzard;David A. Cooper;José Gatell

  • Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

    Patrick G. Yeni;Scott M. Hammer;Martin S. Hirsch;Michael S. Saag

  • Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome.

    John C Walsh;Sundhiya Mandalia;Brian G Gazzard

  • Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

    Mark E. Sharkey;Ian Teo;Thomas Greenough;Natalia Sharova

  • Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection

    Thomas Powles;David Robinson;Justin Stebbing;Jonathan Shamash

  • Increasing burden of liver disease in patients with HIV infection

    Deepak Joshi;John O'Grady;Doug Dieterich;Brian Gazzard

  • Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.

    Cormac Cosgrove;James E. Ussher;Andri Rauch;Kathleen Gärtner

  • Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.

    Scott M Hammer;Michael S Saag;Mauro Schechter;Julio S G Montaner

  • Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

    Jose R. Arribas;Anton L. Pozniak;Joel E. Gallant;Edwin DeJesus

  • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

    Frank van Leth;Prahpan Phanuphak;Erik Stroes;Brian Gazzard

  • Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma

    M. Bower;M. Nelson;A.M. Young;C. Thirlwell

  • Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV-1 Infection

    Graeme J. Moyle;Adrian Wildfire;Sundhiya Mandalia;Howard Mayer

  • Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

    Anton L. Pozniak;Joel E. Gallant;Joel E. Gallant;Edwin DeJesus;Jose R. Arribas;Jose R. Arribas

  • Relation between HIV viral load and infectiousness : a model-based analysis. Commentary

    Geoffrey P. Garnett;Brian Gazzard;David P. Wilson;Matthew G. Law

Frequent Co-Authors

Mark Nelson
Mark Nelson University of Vermont
Mark Bower
Mark Bower Imperial College London
Justin Stebbing
Justin Stebbing Imperial College London
Graeme Moyle
Graeme Moyle Chelsea and Westminster Hospital NHS Foundation Trust
Anton Pozniak
Anton Pozniak London School of Hygiene & Tropical Medicine
Martin Fisher
Martin Fisher University of Sussex
Frances Gotch
Frances Gotch Imperial College London
Mark Nelson
Mark Nelson Imperial College London
Philippa Easterbrook
Philippa Easterbrook King's College London
Caroline Sabin
Caroline Sabin University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine, it’s important to know there are multiple educational pathways and related degrees that lead to promising healthcare roles. For those interested in practical nursing, entry requirements may vary, and you might wonder: do I need to take the TEAS test for LPN? Exploring programs with flexible prerequisites can open doors for aspiring nurses.

Healthcare is more than direct patient care. If you're intrigued by the business side of medicine, a healthcare administration degree can prepare you for leadership roles in hospitals, clinics, and health organizations—many of which are offered online for busy professionals.

Career advancement is also accessible through bridge programs like RN to NP programs, which allow registered nurses to become nurse practitioners while completing their education online or in hybrid formats.

For those interested in wellness and prevention, earning an online degree in nutrition offers a science-based path into patient care, community health, and health education.

Whether you’re at the start of your journey or looking to specialize, these online degrees and pathways provide flexible options to build a rewarding healthcare career in the USA.

Best Scientists Citing Brian Gazzard

Trending Scientists

Recently Published Articles